Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02961062 · ClinicalTrials.gov registry record · Phase 2
Study of SAF312 as an Eye Drop for Treatment of Eye Pain Following Photorefractive Keratectomy (PRK) Surgery
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT02961062 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 40 participants.
The verdict
NCT02961062, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if SAF312 eye drops have an adequate safety and efficacy profile to justify further clinical development for the treatment of ocular pain associated with corneal epithelial defect such as after photorefractive keratectomy (PRK) surgery
Interventions
- DRUG Placebo
- DRUG SAF312
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2016-12-01 |
| Est. Completion | 2018-02-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02961062
The ClinicalTrials.gov registry entry for NCT02961062 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02961062 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02961062 about?
NCT02961062 is a clinical study titled "Study of SAF312 as an Eye Drop for Treatment of Eye Pain Following Photorefractive Keratectomy (PRK) Surgery". The purpose of this study is to determine if SAF312 eye drops have an adequate safety and efficacy profile to justify further clinical development for the treatment of ocular pain associated with corneal epithelial defect such as after photorefractive keratectomy (PRK) surgery
What is the current status of trial NCT02961062?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2016-12-01. Estimated completion is 2018-02-21.
What interventions are being tested in trial NCT02961062?
The interventions under investigation include: Placebo (DRUG), SAF312 (DRUG).
Who is sponsoring clinical trial NCT02961062?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.